Neurocognitive Dysfunction Clinical Trial
— ButyrateOfficial title:
Microbiome Targeted Oral Butyrate Therapy in Gulf War Multisymptom Illness
The primary objective of this clinical trial is to determine if treatment with Butyrate formulation that consists of butyric acid as calcium and magnesium derivatives (Ca-Mg Butyrate) improves the physical function of men and women Veterans suffering from Gulf War Illness (GWI). The primary outcome measure is a change from baseline on the Short Form Health Survey 36-item (VSF-36), with respect to physical functioning and symptoms. The secondary outcome will focus on the drug's role in (a) restoring gut microbiome and virome, (b) decreasing gastrointestinal disturbances (constipation, diarrhea, pain), (c) decreasing chronic fatigue, (d) decreasing systemic inflammation, and (e) a decrease in cognitive deficits.
Status | Recruiting |
Enrollment | 120 |
Est. completion date | March 31, 2026 |
Est. primary completion date | January 10, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years to 70 Years |
Eligibility | Inclusion Criteria: - Gulf war era veteran deployed 40 and 70 years old, in good health by medical history prior to 1990 meeting GWI case definition of CDC and Kansas criteria and - currently have no exclusionary diagnoses (self- reported) that could reasonably explain the symptoms of their fatiguing illness. The severity of illness is moderate to severe, scoring less than 30 of 100 on the physical domain of VSF36 . Exclusion Criteria: - Untreated schizophrenia, - Untreated bipolar disorder, - Untreated delusional disorders, - Untreated dementias of any type and - active alcoholism or drug abuse. - Medical conditions excluded include (i) organ failure, (ii) defined rheumatologic inflammatory disorders, and (iii) transplant. - Use of Butyrate in any form in the 3 months prior to study drug, medications that would impact gut motility, diarrhea, chronic pain, and immune function e.g., steroids, (Last 3 months) - immunosuppressive drugs or biologic response modifiers within 3 months of study entry will be used as exclusion criteria. - Pregnancy, or planned pregnancy in the next 6 months, - Body mass index more than 35 - Specific diets that may have enhanced or enriched fiber or butyrogenic formulations (FODMAP) - Medications that could potentially impact immune function in the past one month will be excluded (e.g., steroids, antibiotics, immunosuppressives; - Medications containing supplement calcium or magnesium butyrate should not be taken for at least 3 months before study entry. - Nutraceuticals that are formulated to impact gut microbiome or immune health) and use of drugs that affect GI motility and use of any antibiotic in the last 2 months. - Known allergy to butyrate supplements or their derivatives such as sodium salts or hydroxy derivatives of butyrate and/or inactive ingredients of active and placebo soft gelatin will also be excluded. - Current evidence of celiac disease or late-stage cirrhosis of the liver, Giardia antigen presence, Clostridium difficile toxin in stool, tissue transglutaminase antibody, recent change in gastrointestinal medications, use of drugs that affects gastrointestinal motility, and use of any antibiotic in the last two months also will be excluded. |
Country | Name | City | State |
---|---|---|---|
United States | VA Long Beach Healthcare System, Long Beach, CA | Long Beach | California |
United States | Miami VA Healthcare System, Miami, FL | Miami | Florida |
United States | VA Salt Lake City Health Care System, Salt Lake City, UT | Salt Lake City | Utah |
Lead Sponsor | Collaborator |
---|---|
VA Office of Research and Development | Miami VA Healthcare System, VA Salt Lake City Health Care System |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Veterans Short Form 36-Item Health Survey Physical Component Summary | Veterans Health Survey contains 36 items to measure health functioning from the patient's point of view. Qualify of life will be determined per Short Form-36 for Veterans' quality of life Physical component (PCS) summary scales, range from 0 to 100 with 100 being better; 50 is expected population average. | Change from Baseline at 3, 6, 9, 12, 18 and 20 weeks | |
Secondary | California Verbal Learning Test (CVLT-II) | CVLT-II asks questions about cognitive symptoms related to recall and memory. The CVLT-II is used to measure verbal learning and episodic long-term memory. It assesses learning, short- and long-delayed recall and recognition for a list of 16 shopping items. Subjects are expected to remember a list of words. They are asked to repeat the words remembered 5 times (5 trials). Each of the words correctly remembered, in each trial, is marked as 1 point. The reported data represent the number of correct items for the Trial 1-Trial 5, Short Delay Free Recall, and Long Delay Free Recall. The long-delayed recall is assessed at 20 minutes. The CVLT enables a comprehensive characterization of a participant's memory profile. Scale ranges from 0 to 80 with 80 being the best. | Change from Baseline at 9, 18 and 20 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04005456 -
Personalized Lifestyle Intervention for Improving Functional Health Outcomes Using N-of-1 Tent-Umbrella-Bucket Design
|
N/A | |
Enrolling by invitation |
NCT06227962 -
Cognitive Functioning and Health Related Quality of Life in Retinoblastoma Survivors
|
||
Completed |
NCT04038788 -
Add-on HD Hf-tRNS Over Bilateral DLPFC for Treating Patients With Schizophrenia
|
N/A | |
Withdrawn |
NCT01186289 -
Statin Therapy To Limit Cognitive Dysfunction After Cardiac Surgery
|
N/A | |
Recruiting |
NCT05077748 -
An 18-year Follow-up Study on OSA in a Population-based Cohort
|
||
Recruiting |
NCT03606421 -
CBF and NCF Changes With Brain Radiation
|
||
Recruiting |
NCT03709199 -
Long Term Follow up of Children Enrolled in the REDvent Study
|
||
Recruiting |
NCT04458207 -
Cognitive Changes and Neural Correlates After Rehabilitation of Masticatory Function in Elderly -an Intervention Study
|
N/A | |
Recruiting |
NCT05363332 -
Impact and Sequelae of High Ventilatory Drive in Critically Ill COVID-19 Patients
|
||
Recruiting |
NCT03886675 -
Intervention With Cerebral Embolic Protection in TEVAR: Gaseous Protection
|
N/A | |
Enrolling by invitation |
NCT04373525 -
Prospective Evaluation on Cognitive Function and Its Associated Genetic Vulnerability in Cannabis Users
|
||
Enrolling by invitation |
NCT04881266 -
Long-Term Functional, Quality-of-Life, Neuropsychological and Cognitive Outcomes in COVID-19 Critical Illness Survivors
|
||
Completed |
NCT03795454 -
Can Singing Kangaroo Improve Outcome of Preterm Infants
|
N/A | |
Recruiting |
NCT05019300 -
Long-term Neurocognitive and Psychiatric Consequences in Severe COVID-19 Survivors.
|
||
Not yet recruiting |
NCT05245903 -
Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside
|
||
Terminated |
NCT03163277 -
Using Less Neurotoxic Drugs in Patients With HAND (MARAND-X)
|
Phase 4 | |
Not yet recruiting |
NCT06224088 -
Neuro-cognitive Function 1 Year Post ICU Discharge Among VV ECMO Survivors
|
||
Completed |
NCT03460821 -
Validation of a German Translation and Cultural Adaptation of the Addenbrooke's Cognitive Examination III
|
||
Not yet recruiting |
NCT06413173 -
Remotely Supervised tDCS+ for Complex Attention in mTBI (Cognetric)
|
N/A | |
Terminated |
NCT03863639 -
Changes in fMRI and Neurocognitive Function in Women With Pre-eclampsia
|